NexGel manufactures electron beam cross linked hydrogels for wound care medical diagnostics transdermal drug delivery and cosmetics.
The company operates as a contract manufacturer supplying gels to third parties who incorporate them into their own products.
It also offers a line of branded consumer products sold direct to consumer through electronic commerce retail and medical office channels.
Additionally NexGel provides custom and white label opportunities that let other…
NexGel manufactures electron beam cross linked hydrogels for wound care medical diagnostics transdermal drug delivery and cosmetics.
The company operates as a contract manufacturer supplying gels to third parties who incorporate them into their own products.
It also offers a line of branded consumer products sold direct to consumer through electronic commerce retail and medical office channels.
Additionally NexGel provides custom and white label opportunities that let other brands create finished hydrogel products which they can then brand and re sell.
Revenue is derived from the sale of hydrogels to contract manufacturing customers.
Revenue also comes from the sale of branded consumer products via electronic commerce retail partnerships and specialized medical office distributors.
Further income is generated from development fees and product sales associated with custom and white label offerings including the joint venture CG Converting and Packaging LLC which expands finished goods capacity.
The company organizes its operations into four reportable segments: Contract Manufacturing Consumer Products Custom and White Label Opportunities and Medical Devices.
• Contract Manufacturing involves the manufacture and supply of electron beam cross linked hydrogels to third parties for use in drug delivery other medical applications non prescription therapeutic applications moist wound and burn dressings components of medical devices and cosmetic applications.
The company's 13 500 square foot facility in Langhorne Pennsylvania operates at 15 to 20 percent capacity with the ability to scale up to approximately 1 point 4 billion square inches of product annually.
Through its 50 percent interest in the CG Converting and Packaging LLC joint venture NexGel subleases 6 200 square feet in Granbury Texas to expand finished goods delivery to its growing customer base.
• Consumer Products include branded lines such as Medagel SilverSeal Hexagels Turfguard Kenkoderm and Silly George which are sold direct to consumer through electronic commerce retail partnerships and specialized medical office channels.
The Medagel family focuses on over the counter remedy solutions like blister and pain applications while Kenkoderm addresses skincare for consumers with psoriasis and Silly George targets beauty with false eyelashes and related eye products.
NexGel continues to develop new products targeting over the counter pharmaceutical drug delivery pain management beauty cosmetics sports applications cannabinoids and podiatry and pursues a roll up strategy through potential acquisitions.
• Custom and White Label Opportunities allow other over the counter brands to incorporate hydrogels into their products by paying a development fee that eliminates NexGel's financial risk in the success or failure of the custom product.
Unlike the contract manufacturing model where bulk roll stock hydrogel is supplied for further processing this approach delivers a finished product that the customer can brand and re sell.
The offering is particularly attractive to beauty and cosmetics companies seeking paraben free formulations and personalized color texture options.
• Medical Devices focuses on developing products such as the NEXDrape incise surgical drape and the NEXDerm adhesive tape for securing lines to reduce skin pain and irritation.
Proof of concept studies using animal and human cadaver models support the belief that NEXDrape provides a gentle to the skin alternative to current adhesive drapes and can deliver antiseptic and antibiotic agents while preventing air bubbles and dermis removal.
NEXDerm is designed to incorporate exclusively licensed X Static silver fiber technology to allow easy repositioning pain free removal gentle to skin contact and increased infection prevention over existing products such as Tegaderm.
NexGel intends to file 501(k) premarket submissions with the FDA to demonstrate substantial equivalence but plans to commercialize these devices through licensing or partnering arrangements with third parties rather than direct sales.
NexGel is one of only two manufacturers that use electron beam technology to produce high performance hydrogels for the wound care cosmetic and drug delivery industries giving it a niche position with limited direct competition in its contract manufacturing business.
In the consumer products and medical device areas the company faces competition from large established firms such as Johnson & Johnson Pfizer Consumer Healthcare and Procter & Gamble.
Competitive advantages stem from its proprietary manufacturing process that avoids chemical cross linking agents making its gels gentler to skin its ability to meet tight tolerance specifications for thickness water content adhesion absorption moisture vapor transmission rate and release rate and its broad selection of liners that allow customization of color texture and performance.
The company's dedicated manufacturing facility and compliance with FDA current good manufacturing practice requirements create a high barrier to entry for potential competitors.
Additionally NexGel's portfolio of patents trade secrets and ongoing technological innovations helps protect its market position.
The company serves a diverse base of contract manufacturing customers that integrate its hydrogels into a wide range of end products including drug delivery patches wound dressings medical device components and cosmetic items.
It also sells directly to consumers who purchase its branded over the counter skincare beauty and remedy solutions through electronic commerce platforms retail stores and medical office distributors.
Furthermore NexGel works with other over the counter brands seeking custom or white label hydrogel solutions to incorporate its technology into their own product lines.
During the years ended December 31 2024 and 2025 no single customer accounted for ten percent or more of total revenue indicating a broadly diversified customer base.
Sectors:Healthcare · Consumer StaplesSector rationaleThe company's primary business is the manufacture of medical-grade hydrogels for wound care, medical diagnostics, and transdermal drug delivery, serving as a contract manufacturer for medical device components and developing FDA-regulated medical devices like NEXDrape. A secondary sector is justified because the company also operates a substantial branded consumer business selling beauty, cosmetics, and skincare products (e.g., Silly George and Kenkoderm) through retail and e-commerce channels, which falls under Consumer Staples.Industries:+1 moreContract ManufacturingHealthcarePrimaryNexGel operates as a contract manufacturer supplying electron beam cross linked hydrogels to third parties for use in drug delivery, medical applications, and wound dressings. Revenue is explicitly derived from the sale of these hydrogels to contract manufacturing customers who incorporate them into their own products.Medical DevicesHealthcareSecondaryThe company has a dedicated Medical Devices segment developing products like the NEXDrape incise surgical drape and NEXDerm adhesive tape for securing lines.Personal Care ProductsConsumer StaplesSecondaryNexGel sells branded over-the-counter consumer products such as Medagel for blisters and pain, and Kenkoderm for psoriasis, through e-commerce and retail channels.Classified using BQ-MICSCIK: 0001468929
Investment Thesis
▲ Bull case
The acquisition of BioNX brings six commercial stage regenerative biomaterial products that have more than a decade of clinical use and already enjoy reimbursement pathways in approximately five hundred hospitals across the United States. This established base provides a platform for immediate sales generation without the need for lengthy regulatory approvals or market education efforts. The company notes that these products span multiple surgical specialties and wound care offering diversification beyond the legacy hydrogel portfolio. With the recent appointment of Dave Hazard as vice president of sales for BioNX Surgical the firm gains a leader with over thirteen years of experience building scalable sales infrastructures in orthopedics spine and biologics which should accelerate hospital adoption and drive repeatable revenue streams.
The partnership with Sequence LifeScience not only replaced a short term lender with a long term strategic investor but also added manufacturing capabilities product development expertise and an established distribution network that can be leveraged across both the BioNX portfolio and NEXGEL's existing hydrogel products. Sequence's representatives Brian Keeser and Kevin Harris have joined the board bringing deep industry experience and a track record of scaling medical technology businesses. This alignment reduces execution risk associated with integrating the acquired division and provides a clear pathway to achieve the pro forma revenue target of roughly $35,000,000 annually. The collaboration also opens avenues for joint product development efforts that could expand the pipeline beyond the three 510(k) devices currently in development. Overall the partnership is positioned to create synergies that enhance gross margins and accelerate market penetration.
Legacy businesses are showing signs of recovery that exceed the conservative assumptions used in the company's guidance with Silly George sales normalizing in April after a weak fourth quarter and first quarter performance. The STADA line within the MEDAGEL portfolio has experienced steady growth following its February launch despite initial Amazon stickering delays indicating healthy consumer demand for the new offerings. Contract manufacturing revenues have also increased partially offsetting the decline in Silly George and demonstrating the flexibility of the hydrogel platform to serve third party customers. Management expects continued growth in the tropoelastin line as shipments from Germany arrive and products are listed on Amazon in the next sixty days providing another avenue for expansion. Taken together these trends suggest that the core business could contribute more than the modest 10% growth built into the current forecast.
The iRhythm relationship while currently modest represents a potential catalyst for increased order volumes as the partner expands its own sales efforts and the gel pad becomes a standard component in its monitoring devices. Beyond iRhythm the company notes a pipeline of additional contract manufacturing opportunities that could contribute $200,000 or more in quarterly revenue if they materialize. The gel platform's versatility allows rapid adaptation to new customer specifications without significant retooling costs which enhances the attractiveness of NEXGEL as a contract manufacturing partner. Management's acknowledgment of a growing funnel indicates that the business development team is actively pursuing new accounts that could diversify revenue streams away from consumer volatility. Successfully converting even a fraction of these prospects would meaningfully boost top line growth and improve operating leverage.
Financial strengthening efforts have increased liquidity and improved the balance sheet with the closing of the BioNX transaction supported by an $8,800,000 cash infusion and a $5,000,000 convertible note provided to Cellularity. The subsequent $5,500,000 investment from Sequence LifeScience further bolsters cash reserves and replaces a near term lender with a long term strategic partner. The appointment of Ian Blackman as chief financial officer brings extensive M&A and financial leadership experience that should aid in integrating the acquisition and optimizing cost structure. With cash on hand reported at approximately $1,800,000 and additional fundraising largely completed the company has sufficient working capital to support sales expansion research and development and potential working capital needs. This financial foundation reduces the risk of liquidity constraints and enables management to pursue growth initiatives without urgent financing pressures.
The acquisition of BioNX brings six commercial stage regenerative biomaterial products that have more than a decade of clinical use and already enjoy reimbursement pathways in approximately five hundred hospitals across the United States. This established base provides a platform for immediate sales generation without the need for lengthy regulatory approvals or market education efforts. The company notes that these products span multiple surgical specialties and wound care offering diversification beyond the legacy hydrogel portfolio. With the recent appointment of Dave Hazard as vice president of sales for BioNX Surgical the firm gains a leader with over thirteen years of experience building scalable sales infrastructures in orthopedics spine and biologics which should accelerate hospital adoption and drive repeatable revenue streams.
The partnership with Sequence LifeScience not only replaced a short term lender with a long term strategic investor but also added manufacturing capabilities product development expertise and an established distribution network that can be leveraged across both the BioNX portfolio and NEXGEL's existing hydrogel products. Sequence's representatives Brian Keeser and Kevin Harris have joined the board bringing deep industry experience and a track record of scaling medical technology businesses. This alignment reduces execution risk associated with integrating the acquired division and provides a clear pathway to achieve the pro forma revenue target of roughly $35,000,000 annually. The collaboration also opens avenues for joint product development efforts that could expand the pipeline beyond the three 510(k) devices currently in development. Overall the partnership is positioned to create synergies that enhance gross margins and accelerate market penetration.
Legacy businesses are showing signs of recovery that exceed the conservative assumptions used in the company's guidance with Silly George sales normalizing in April after a weak fourth quarter and first quarter performance. The STADA line within the MEDAGEL portfolio has experienced steady growth following its February launch despite initial Amazon stickering delays indicating healthy consumer demand for the new offerings. Contract manufacturing revenues have also increased partially offsetting the decline in Silly George and demonstrating the flexibility of the hydrogel platform to serve third party customers. Management expects continued growth in the tropoelastin line as shipments from Germany arrive and products are listed on Amazon in the next sixty days providing another avenue for expansion. Taken together these trends suggest that the core business could contribute more than the modest 10% growth built into the current forecast.
The iRhythm relationship while currently modest represents a potential catalyst for increased order volumes as the partner expands its own sales efforts and the gel pad becomes a standard component in its monitoring devices. Beyond iRhythm the company notes a pipeline of additional contract manufacturing opportunities that could contribute $200,000 or more in quarterly revenue if they materialize. The gel platform's versatility allows rapid adaptation to new customer specifications without significant retooling costs which enhances the attractiveness of NEXGEL as a contract manufacturing partner. Management's acknowledgment of a growing funnel indicates that the business development team is actively pursuing new accounts that could diversify revenue streams away from consumer volatility. Successfully converting even a fraction of these prospects would meaningfully boost top line growth and improve operating leverage.
Financial strengthening efforts have increased liquidity and improved the balance sheet with the closing of the BioNX transaction supported by an $8,800,000 cash infusion and a $5,000,000 convertible note provided to Cellularity. The subsequent $5,500,000 investment from Sequence LifeScience further bolsters cash reserves and replaces a near term lender with a long term strategic partner. The appointment of Ian Blackman as chief financial officer brings extensive M&A and financial leadership experience that should aid in integrating the acquisition and optimizing cost structure. With cash on hand reported at approximately $1,800,000 and additional fundraising largely completed the company has sufficient working capital to support sales expansion research and development and potential working capital needs. This financial foundation reduces the risk of liquidity constraints and enables management to pursue growth initiatives without urgent financing pressures.
The integration of the BioNX division faces multiple operational hurdles that could delay the anticipated revenue ramp including the need to reengage the sales force after obtaining updated contracts that comply with Sunshine Laws and other regulatory requirements. Management acknowledged that as of the call date they were only just beginning to send out contracts and retrain representatives meaning the effective selling period for the acquired products may be shorter than the assumed half of the second quarter. Additional tasks such as updating vendor records and renaming accounts from Cellularity to BioNX in hospital systems add administrative friction that consumes time and resources. If these integration steps take longer than expected the contribution from BioNX to quarterly revenue could fall short of the pro forma estimates undermining the expected accretive impact on profitability.
Reliance on Sequence LifeScience as a strategic manufacturing and distribution partner introduces concentration risk because any disruption in the relationship could leave NEXGEL without an alternative source for producing its BioNX portfolio or scaling its hydrogel products. While the partnership replaces a near term lender with a long term investor the alignment of incentives has not yet been tested through a full commercial cycle and there is no guarantee that Sequence will prioritize NEXGEL's projects over its own internal initiatives. The company's ability to achieve the projected $35,000,000 pro forma revenue depends heavily on Sequence's capacity to expand manufacturing output and distribute products to the existing five hundred hospital network. If Sequence encounters capacity constraints or shifts its strategic focus the anticipated synergies may not materialize leaving NEXGEL to bear the full cost of integration without the expected offsetting benefits. Investors should monitor the depth of the partnership beyond board representation to assess whether operational collaboration will translate into tangible sales growth.
The legacy consumer business remains exposed to volatile trends and intense competition which could prevent the anticipated recovery in Silly George STADA and MEDAGEL from sustaining beyond a short term bounce. Management noted that the weak performance of the lip gloss extension and the broader downturn in pop culture driven products were partly responsible for the recent softness indicating that success in this segment is highly dependent on hitting consumer preferences that can change rapidly. Even with the addition of new items such as tweezers the overall category may continue to face pressure from larger rivals that have greater marketing budgets and shelf space in mass retail channels. Should the consumer business fail to generate meaningful growth the company would become overly reliant on the BioNX division to meet its revenue targets increasing execution pressure on a newly integrated segment. This concentration would heighten vulnerability to any setbacks in the regenerative medicine business and could lead to earnings volatility that worries investors.
The pipeline of three 510(k) devices represents a significant investment of approximately $4,600,000 in paid in capital yet commercialization timelines stretch into 2027 2026 and 2020 which raises concerns about the ability to recoup these expenses in a timely manner. Regulatory clearance for medical devices is inherently uncertain and any delay or rejection by the FDA would directly impact the expected revenue contribution from these projects. Furthermore the company has not disclosed detailed milestones or success probabilities for each program making it difficult for investors to gauge the likelihood of achieving the anticipated upside. Should one or more of these devices encounter setbacks the sunk capital would weigh on the balance sheet and could necessitate additional fundraising or cost cutting measures elsewhere in the organization. The long horizon also means that the opportunity cost of capital tied up in these projects could be considerable especially if alternative higher returning investments become available.
Operating expenses are set to rise substantially as the company expands its sales force invests in research and development for the BioNX pipeline and integrates the acquired division potentially pressuring profitability even if revenue targets are met. The CFO indicated a monthly run rate of approximately $500,000 for all in salaries marketing commissions and related costs which translates to an annual expense base of roughly $6,000,000 before accounting for additional costs tied to the new sales initiatives and pipeline development. With cash on hand of about $1,800,000 and the recent fundraising largely completed the company may need to rely on future cash flows or additional financing to sustain operations if revenue growth lags behind expense increases. The convertible note and any further equity offerings could dilute existing shareholders reducing upside potential per share. Moreover the company's history of missing expectations on consumer product launches raises doubts about its ability to execute complex integration plans without encountering unforeseen costs or delays.
The integration of the BioNX division faces multiple operational hurdles that could delay the anticipated revenue ramp including the need to reengage the sales force after obtaining updated contracts that comply with Sunshine Laws and other regulatory requirements. Management acknowledged that as of the call date they were only just beginning to send out contracts and retrain representatives meaning the effective selling period for the acquired products may be shorter than the assumed half of the second quarter. Additional tasks such as updating vendor records and renaming accounts from Cellularity to BioNX in hospital systems add administrative friction that consumes time and resources. If these integration steps take longer than expected the contribution from BioNX to quarterly revenue could fall short of the pro forma estimates undermining the expected accretive impact on profitability.
Reliance on Sequence LifeScience as a strategic manufacturing and distribution partner introduces concentration risk because any disruption in the relationship could leave NEXGEL without an alternative source for producing its BioNX portfolio or scaling its hydrogel products. While the partnership replaces a near term lender with a long term investor the alignment of incentives has not yet been tested through a full commercial cycle and there is no guarantee that Sequence will prioritize NEXGEL's projects over its own internal initiatives. The company's ability to achieve the projected $35,000,000 pro forma revenue depends heavily on Sequence's capacity to expand manufacturing output and distribute products to the existing five hundred hospital network. If Sequence encounters capacity constraints or shifts its strategic focus the anticipated synergies may not materialize leaving NEXGEL to bear the full cost of integration without the expected offsetting benefits. Investors should monitor the depth of the partnership beyond board representation to assess whether operational collaboration will translate into tangible sales growth.
The legacy consumer business remains exposed to volatile trends and intense competition which could prevent the anticipated recovery in Silly George STADA and MEDAGEL from sustaining beyond a short term bounce. Management noted that the weak performance of the lip gloss extension and the broader downturn in pop culture driven products were partly responsible for the recent softness indicating that success in this segment is highly dependent on hitting consumer preferences that can change rapidly. Even with the addition of new items such as tweezers the overall category may continue to face pressure from larger rivals that have greater marketing budgets and shelf space in mass retail channels. Should the consumer business fail to generate meaningful growth the company would become overly reliant on the BioNX division to meet its revenue targets increasing execution pressure on a newly integrated segment. This concentration would heighten vulnerability to any setbacks in the regenerative medicine business and could lead to earnings volatility that worries investors.
The pipeline of three 510(k) devices represents a significant investment of approximately $4,600,000 in paid in capital yet commercialization timelines stretch into 2027 2026 and 2020 which raises concerns about the ability to recoup these expenses in a timely manner. Regulatory clearance for medical devices is inherently uncertain and any delay or rejection by the FDA would directly impact the expected revenue contribution from these projects. Furthermore the company has not disclosed detailed milestones or success probabilities for each program making it difficult for investors to gauge the likelihood of achieving the anticipated upside. Should one or more of these devices encounter setbacks the sunk capital would weigh on the balance sheet and could necessitate additional fundraising or cost cutting measures elsewhere in the organization. The long horizon also means that the opportunity cost of capital tied up in these projects could be considerable especially if alternative higher returning investments become available.
Operating expenses are set to rise substantially as the company expands its sales force invests in research and development for the BioNX pipeline and integrates the acquired division potentially pressuring profitability even if revenue targets are met. The CFO indicated a monthly run rate of approximately $500,000 for all in salaries marketing commissions and related costs which translates to an annual expense base of roughly $6,000,000 before accounting for additional costs tied to the new sales initiatives and pipeline development. With cash on hand of about $1,800,000 and the recent fundraising largely completed the company may need to rely on future cash flows or additional financing to sustain operations if revenue growth lags behind expense increases. The convertible note and any further equity offerings could dilute existing shareholders reducing upside potential per share. Moreover the company's history of missing expectations on consumer product launches raises doubts about its ability to execute complex integration plans without encountering unforeseen costs or delays.